Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Apollomics
company
About
Apollomics is a biopharmaceutical company discovering and developing mono- and combination- oncology therapies to harness the immune system.
- 101 - 250
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $100M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2016
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Apollomics, Inc. is an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s existing pipeline consists of several development-stage assets, including novel, humanized monoclonal antibodies that restore the body’s immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$100M
Apollomics has raised a total of
$100M
in funding over 2 rounds. Their latest funding was raised on
Jan 8, 2019 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 8, 2019 | Series B | $100M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Apollomics is funded by 1 investors.
Guangzhou Yue Min Investment
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
